Systematic review of 54 RCTs found limited evidence for cannabinoids treating mental health conditions. Most robust findings for cannabis use disorder, but overall quality low.
[read the full story...]
13% of vapes confiscated from English schools contained synthetic cannabinoids mis-sold as THC. Refillable vapes and social media platforms enable this dangerous trend.
[read the full story...]
As we prepare for our Cannabis #MHQT event on Wed 26 Sep, Luke Sheridan Rains dissects a narrative review that asks: Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?
His answer is that current evidence does not support the use of medical cannabis for mental illnesses such as anxiety or depression.
[read the full story...]
Derek Tracy takes a first look at the Novel Psychoactive Substances in the UK Project; an NIHR-funded empirical and conceptual review that recommends research priorities in the field.
[read the full story...]
Harry Sumnall, Ian Hamilton and Mark Monaghan provide an overview of Novel Psychoactive Substances (NPS) aimed at health professionals and others who work with people who use these new psychoactive substances.
[read the full story...]
9 case-controlled studies were included in this review of the effect of marijuana use on head and neck cancer. The findings suggest no association marijuana use and head and neck cancer but other reviews suggest that this may differ by tumour site
[read the full story...]
Eleanor Kennedy writes her debut blog on a recent case-control study of people in South London, which explores the links between first-episode psychosis and the use of high potency cannabis (skunk).
[read the full story...]
